日本的抗体治疗药市场:各产品类型，各适应疾病，各给药途径，各终端用户，各地区，机会，预测，2019年～2033年

预计在预测期内（2025-2033 年），日本抗体治疗市场规模将以 10% 的复合年增长率增长，从 2025 年的 193.3 亿美元增长至 2033 年的 414.4 亿美元。受近期技术趋势和对有效治疗解决方案的迫切需求的推动，日本治疗性抗体市场正在经历强劲增长。市场扩张的主要因素之一是癌症和心血管疾病等慢性疾病的发生率不断增加，进而促使製造业业务的增加。

例如，Epkinly™（通用名：epcolitamab）已获得厚生劳动省的批准，是日本第一个也是唯一一个获批用于治疗某些復发或难治性大B细胞淋巴瘤（LBCL）成年患者的T细胞介导双特异性抗体。这包括瀰漫大 B 细胞淋巴瘤 (DLBCL)、高级别 B 细胞淋巴瘤 (HGBCL)、原发性纵隔大 B 细胞淋巴瘤 (PMBCL) 和 3B 级滤泡性淋巴瘤 (FL3B)。 Epcolitamab 是 Genmab 和 AbbVie 肿瘤学合作的一部分。

本报告提供日本的抗体治疗药市场相关调查，提供市场概要，以及各产品类型，各适应疾病，各给药途径，各终端用户，各地区趋势，及加入此市场的主要企业的简介等资讯。

目录

第1章 计划的范围和定义

第2章 调查手法

第3章 摘要整理

第4章 日本的抗体治疗药市场预测，2019年～2033年

• 市场规模分析与预测
• 市场占有率分析与预测
• 2025年市场地图分析
  • 各产品类型
  • 各适应疾病
  • 各给药途径
  • 各终端用户
  • 各地区

第5章 需求供给分析

第6章 价值链分析

第7章 波特的五力分析

第8章 大环境分析

第9章 价格分析

第10章 市场动态

• 市场促进因素
• 市场课题

第11章 市场趋势与发展

第12章 法规情形

第13章 临床试验概要

第14章 案例研究

第15章 竞争情形

• 市场领导前五名的竞争矩阵
• 参与企业前五名的SWOT分析
• 市场前10名的主要企业的形势
  • AbbVie Inc.
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services Inc.
  • Amgen Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • AstraZeneca plc
  • Eli Lilly and Company

第16章 策略性建议

第17章 关于调查公司·免责声明

Japan antibody therapeutics market is projected to witness a CAGR of 10% during the forecast period FY2025-FY2033, growing from USD 19.33 billion in FY2025 to USD 41.44 billion in FY2033. Japan market for antibody therapeutics has grown significantly because of recent developments in technology and the urgent need for effective therapeutic solutions. One of the main reasons for driving market expansion is the increasing frequency of chronic diseases such as cancer and cardiovascular disorders, which has increased manufacturing operations.

For example, the Japan Ministry of Health, Labour and Welfare has granted approval to EPKINLY(TM) (epcoritamab), making it the first and only T-cell engaging bispecific antibody approved in Japan for the treatment of adult patients with certain relapsed or refractory large B-cell lymphoma (LBCL) types. This includes diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B), after two or more prior lines of systemic therapy. Epcoritamab is co-developed by Genmab and AbbVie under their oncology collaboration.

Increasing Prevalence of Chronic Diseases and Aging Population Driving Market Demand

Japan has one of the world's oldest populations, with more than 28% of its residents aged 65 and older. This demographic shift has led to a surge in age-related diseases, particularly cancer, autoimmune disorders, and neurological conditions, which are major targets for antibody therapeutics. The rising burden of these diseases is increasing the demand for monoclonal antibodies (mAbs) and polyclonal antibodies, as they offer targeted treatment with fewer side effects compared to traditional therapies. Additionally, the high prevalence of rheumatoid arthritis, multiple sclerosis, and inflammatory diseases in Japan is further driving the adoption of antibody-based treatments. For instance, the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Roche's Polivy (polatuzumab vedotin) for the first-line treatment of diffuse large B-cell lymphoma (DLBCL) in combination with chemotherapy. In December 2024, Roche presented five-year follow-up data from the phase III POLARIX study, reinforcing the potential of Polivy in combination with R-CHP to provide durable and lasting remissions in previously untreated DLBCL. This approval marked a significant advancement in the antibody therapeutics space, providing a new treatment option for a disease that accounts for 30-40% of all non-Hodgkin lymphoma cases in Japan. The increasing number of such approvals is expected to propel the growth of the antibody therapeutics market, as more patients gain access to life-saving biologics.

Rising Investments and Collaborations in Antibody Drug Development

Japan's pharmaceutical sector is witnessing substantial investments and strategic collaborations to advance antibody drug discovery and development. Leading pharmaceutical firms and biotech companies are expanding their biologics research and development (R&D) activities in Japan to leverage the country's expertise in biotechnology and precision medicine. With government support for biopharmaceutical innovations, the market for antibody therapeutics is experiencing rapid expansion. For instance, in August 2023, ImmunoGen, Inc. entered into an exclusive collaboration with Takeda Pharmaceutical Company Limited to develop and commercialize ELAHERE (mirvetuximab soravtansine-gynx) in Japan. ELAHERE is an antibody-drug conjugate (ADC) targeting folate receptor alpha (FRa)-positive, platinum-resistant ovarian cancer. Under the terms of the agreement, ImmunoGen received a USD 34 million upfront payment and is eligible for additional regulatory and commercial milestone payments, as well as double-digit royalties on future net sales in Japan. This collaboration underscores Takeda's commitment to bringing innovative oncology therapies to the Japanese market, addressing significant unmet medical needs.

Increasing Adoption of Subcutaneous Antibody Therapeutics for Patient Convenience

Among the different routes of administration, subcutaneous antibody therapies are gaining popularity in Japan due to greater patient convenience, reduced hospital visits, and lower healthcare costs. Intravenous (IV) infusion, the traditional method of delivering antibody drugs, often requires long hospital stays and high administration costs. However, the introduction of subcutaneous formulations has allowed patients to receive antibody-based treatments at home or in outpatient settings, improving compliance and accessibility. A major development in this segment occurred in January 2024, when Johnson & Johnson's Janssen Pharmaceuticals received approval in Japan for DARZALEX SC (daratumumab), a subcutaneous formulation of its blockbuster multiple myeloma drug. This new version offers shorter administration time and improved patient comfort compared to the intravenous form. With such advancements, subcutaneous antibody therapies are expected to gain a larger market share in Japan, particularly for chronic conditions like cancer, autoimmune diseases, and hematological disorders. As more subcutaneous antibody drugs receive regulatory approvals, the segment will continue to expand, driving overall market growth.

Future Market Scenario (FY2026 - FY2033F)

Many factors claim the growth of Japan antibody therapeutics market. Technological and infrastructural advancements give better results after the diagnosis of the disease. For instance, Astellas has committed USD 256 million to expand its antibody and cell therapy operations in both Japan and the United States. The investment will support the company's future pipeline by building two multi-modality facilities in Japan and relocating a regenerative medicine plant in Massachusetts. The expansion, which includes sites in Toyama and Tsukuba (Japan) and Massachusetts (U.S.), will enhance both R&D and manufacturing capabilities to advance the development and commercialization of Astellas' portfolio. Opportunity also lies in the increasing number of viral infections that the Japan is facing today. Promising moves of the government that provide healthcare infrastructure, funds to carry on research and development on a large scale, and a reliable distribution channel that ensures the solution reaches everyone is testimonial.

Key Players Landscape and Outlook

Key players in the antibody therapeutics industry utilize strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing big-cap industry players to increase their presence and, therefore, find new opportunities in this market.

For instance, in order to improve and broaden the use of ADCs for patients with various cancer types, the partnership combines Merck KGaA's extensive oncology knowledge and clinical development skills with Daiichi Sankyo's demonstrated ADC expertise and DXd technology. With the exception of Japan, where Daiichi Sankyo maintains exclusive rights, Daiichi Sankyo and Merck will jointly develop and market patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan globally.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Japan Antibody Therapeutics Market Outlook, FY2019-FY2033F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Product Type
    • 4.2.1.1. Monoclonal Antibodies
    • 4.2.1.2. Polyclonal Antibodies
    • 4.2.1.3. Others
  • 4.2.2. By Disease Indication
    • 4.2.2.1. Oncology
    • 4.2.2.2. Hematology
    • 4.2.2.3. Immunology
    • 4.2.2.4. Autoimmune and Inflammatory Diseases
    • 4.2.2.5. Neurology
    • 4.2.2.6. Others
  • 4.2.3. By Route of Administration
    • 4.2.3.1. Intravenous
    • 4.2.3.2. Subcutaneous
    • 4.2.3.3. Other Routes of Administration
  • 4.2.4. By End-user
    • 4.2.4.1. Hospitals
    • 4.2.4.2. Long-term Care Centers
    • 4.2.4.3. Others
  • 4.2.5. By Region
    • 4.2.5.1. North [Hokkaido and Tohoku]
    • 4.2.5.2. Central [Kanto and Chubu]
    • 4.2.5.3. South [Kansai, Chugoku, Shikoku, and Kyushu & Okinawa]
  • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2025)
• 4.3. Market Map Analysis, FY2025
  • 4.3.1. By Product Type
  • 4.3.2. By Disease Indication
  • 4.3.3. By Route of Administration
  • 4.3.4. By End-user
  • 4.3.5. By Region

5. Demand Supply Analysis

6. Value Chain Analysis

7. Porter's Five Forces Analysis

8. PESTLE Analysis

9. Pricing Analysis

10. Market Dynamics

• 10.1. Market Drivers
• 10.2. Market Challenges

11. Market Trends and Developments

12. Regulatory Landscape

13. Overview of Clinical Trials

14. Case Studies

15. Competitive Landscape

• 15.1. Competition Matrix of Top 5 Market Leaders
• 15.2. SWOT Analysis for Top 5 Players
• 15.3. Key Players Landscape for Top 10 Market Players
  • 15.3.1. AbbVie Inc.
    • 15.3.1.1. Company Details
    • 15.3.1.2. Key Management Personnel
    • 15.3.1.3. Products and Services
    • 15.3.1.4. Financials (As Reported)
    • 15.3.1.5. Key Market Focus and Geographical Presence
    • 15.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 15.3.2. Bristol-Myers Squibb Co.
  • 15.3.3. F. Hoffmann-La Roche Ltd.
  • 15.3.4. Johnson & Johnson Services Inc.
  • 15.3.5. Amgen Inc.
  • 15.3.6. Merck KGaA
  • 15.3.7. Novartis AG
  • 15.3.8. Pfizer Inc.
  • 15.3.9. AstraZeneca plc
  • 15.3.10. Eli Lilly and Company

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

16. Strategic Recommendations

17. About Us and Disclaimer

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Japan Antibody Therapeutics Market, By Value, In USD Billion, FY2019-FY2033F
• Figure 2. Japan Antibody Therapeutics Market Share (%), By Product Type, FY2019-FY2033F
• Figure 3. Japan Antibody Therapeutics Market Share (%), By Disease Indication, FY2019-FY2033F
• Figure 4. Japan Antibody Therapeutics Market Share (%), By Route of Administration, FY2019-FY2033F
• Figure 5. Japan Antibody Therapeutics Market Share (%), By End-user, FY2019-FY2033F
• Figure 6. Japan Antibody Therapeutics Market Share (%), By Region, FY2019-FY2033F
• Figure 7. By Product Type Map-Market Size (USD Billion) & Growth Rate (%), FY2025
• Figure 8. By Disease Indication Map-Market Size (USD Billion) & Growth Rate (%), FY2025
• Figure 9. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), FY2025
• Figure 10. By End-user Map-Market Size (USD Billion) & Growth Rate (%), FY2025
• Figure 11. By Region Map-Market Size (USD Billion) & Growth Rate (%), FY2025